- Home
- ALTS vs PTN Comparison
ALTS vs PTN Comparison
Compare ALTS & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- PTN
- Stock Information
- Founded
- ALTS 1976
- PTN 1986
- Country
- ALTS United States
- PTN United States
- Employees
- ALTS N/A
- PTN N/A
- Industry
- ALTS
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- ALTS
- PTN Health Care
- Exchange
- ALTS NYSE
- PTN Nasdaq
- Market Cap
- ALTS 28.9M
- PTN 25.4M
- IPO Year
- ALTS N/A
- PTN 1993
- Fundamental
- Price
- ALTS $2.15
- PTN $0.92
- Analyst Decision
- ALTS
- PTN Strong Buy
- Analyst Count
- ALTS 0
- PTN 1
- Target Price
- ALTS N/A
- PTN $17.00
- AVG Volume (30 Days)
- ALTS 127.4K
- PTN 267.1K
- Earning Date
- ALTS 11-29-2024
- PTN 11-14-2024
- Dividend Yield
- ALTS N/A
- PTN N/A
- EPS Growth
- ALTS N/A
- PTN N/A
- EPS
- ALTS N/A
- PTN N/A
- Revenue
- ALTS $7,110,000.00
- PTN $2,384,113.00
- Revenue This Year
- ALTS N/A
- PTN N/A
- Revenue Next Year
- ALTS N/A
- PTN N/A
- P/E Ratio
- ALTS N/A
- PTN N/A
- Revenue Growth
- ALTS N/A
- PTN N/A
- 52 Week Low
- ALTS $0.36
- PTN $0.68
- 52 Week High
- ALTS $5.26
- PTN $5.65
- Technical
- Relative Strength Index (RSI)
- ALTS 44.11
- PTN 38.12
- Support Level
- ALTS $2.00
- PTN $0.90
- Resistance Level
- ALTS $2.49
- PTN $1.26
- Average True Range (ATR)
- ALTS 0.24
- PTN 0.11
- MACD
- ALTS -0.05
- PTN -0.03
- Stochastic Oscillator
- ALTS 20.00
- PTN 4.00
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.